Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

PUBLICATIONS FDA Decisions Expected: July 2025 Your monthly synopsis of new drugs expected to hit the market June 18, 2025 Drug pipeline for July 2025 At Prime Therapeutics (Prime), we have...

Perspectives High-Cost Therapy Profile: March Detailed information about Sotatercept Subcutaneous (SC) High Cost Therapy Profile Cardiovascular Sotatercept Subcutaneous (SC) Merck/Bristol-Myers...

Marquee event showcased new Prime, our energy, ambition and transformative journey

Drug Approvals Quarterly Update: April 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process....

publications High Cost Therapy Profile: January 2025 Tabelecleucel Intravenous (IV) Oncology January 8, 2025 Proposed indications Epstein-Barr virus-positive (EBV+) post-transplant...

publications High-Cost Therapy Profile: June 2025 Zopapogene imadenovec Subcutaneous (SC) | Precigen, Inc. Infectious Disease June 18, 2025 Proposed indications Recurrent respiratory...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care